XML 43 R18.htm IDEA: XBRL DOCUMENT

In-License Agreement	12 Months Ended
In-License Agreement	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
In-License Agreement	In-License Agreement In August 2021, the Company entered into an agreement with Sprint Bioscience (Sprint) to exclusively in-license worldwide rights to a research-stage program targeting VPS34, a key kinase in the autophagy pathway for the potential treatment of cancer (the Sprint Agreement). The Company accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single IPR&D asset. Pursuant to the terms of the Sprint Agreement, the Company made an upfront payment of $4.0 million during the third quarter of 2021, which was recorded as research and development expense within the consolidated statements of operations and comprehensive loss during the year ended December 31, 2021 as the acquired asset had not yet reached technological feasibility. Sprint is also eligible to receive up to an additional $273.0 million in potential development and commercial milestone payments from the Company as well as tiered percentage royalties ranging from the mid-single-digits to the low-double-digits on the sales of a potential product from the program, if approved.